Exhibit 10.14
Execution Version
Amendment No. 1 to Collaboration and LICENSE AGREEMENT
This Amendment No. 1 (“Amendment No. 1”) to the Collaboration and License Agreement dated June 11, 2021 (the “Agreement”) between GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No. 4) LIMITED, a company registered in England and Wales (registered number 11721880) and having business offices at 980 Great West Road, Brentford, Middlesex TW8 9GS United Kingdom (“GSK”), and iTeos Belgium S.A., a public limited company having an office at Rue des Frères Wright, 29, B-6041 Gosselies Belgium (“ITEOS”) is effective as of January 24, 2022 (“Amendment Effective Date”). Each of GSK and ITEOS may be referred to herein as a “Party” and together, the “Parties.”
RECITALS
WHEREAS, GSK and ITEOS desire to amend the Agreement as set forth herein in accordance with Section 17.10.
NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:
Table 12.6 – Development Deadlines | |
Development Milestone Event | Deadline for Achievement |
[***] | [***] |
[***] | [***] |
[***] | [***] |
1
Exhibit 10.14
Execution Version
IN WITNESS WHEREOF, each Party has caused this Amendment No. 1 to be duly executed by its authorized representative on the Amendment Effective Date.
iTeos Belgium, S.A.
/s/ [***] Name: [***] Title: Director
/s/ [***] Name: [***] Title: Director
| GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO. 4 LIMITED
/s/ [***] Name: [***] Title: Corporate Director
|
2